1. Home
  2. EQIX vs REGN Comparison

EQIX vs REGN Comparison

Compare EQIX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equinix Inc. REIT

EQIX

Equinix Inc. REIT

N/A

Current Price

$1,061.74

Market Cap

103.1B

Sector

Real Estate

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$923.41

Market Cap

84.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EQIX
REGN
Founded
1998
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.1B
84.3B
IPO Year
2000
1995

Fundamental Metrics

Financial Performance
Metric
EQIX
REGN
Price
$1,061.74
$923.41
Analyst Decision
Strong Buy
Buy
Analyst Count
35
28
Target Price
★ $1,234.88
$977.93
AVG Volume (30 Days)
632.8K
★ 889.9K
Earning Date
10-28-2026
10-30-2026
Dividend Yield
★ 2.04%
0.42%
EPS Growth
★ 61.88
8.19
EPS
13.96
★ 37.37
Revenue
★ $5,998,545,000.00
$5,872,227,000.00
Revenue This Year
$11.78
$30.96
Revenue Next Year
$11.30
$7.28
P/E Ratio
$72.68
★ $24.27
Revenue Growth
7.85
★ 20.82
52 Week Low
$720.62
$591.52
52 Week High
$1,128.68
$991.73

Technical Indicators

Market Signals
Indicator
EQIX
REGN
Relative Strength Index (RSI) 58.62 65.90
Support Level $1,046.20 $741.03
Resistance Level $1,082.17 N/A
Average True Range (ATR) 36.49 32.76
MACD 7.10 8.82
Stochastic Oscillator 96.11 65.40

Price Performance

Historical Comparison
EQIX
REGN

About EQIX Equinix Inc. REIT

Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: